Chlamydia mRNA Vaccine

Phase 2Vaccine

Sanofi

Chlamydia mRNA Vaccine is one of 6 biologic programs targeting mRNA Vaccine. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MRNA VaccineActive, not recruiting

MRNA VaccinePhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in MRNA Vaccine

#DrugCompanyPhaseTrials

Navmi

SSummit Therapeutics

Phase 1

1 2

Personalized Neoantigen Tumor Vaccine

RRuijin Hospital

Phase 1

1 3

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 1

1 4

Chlamydia mRNA Vaccine

Sanofi

Phase 2

1 5

Mfolforinox

AAkeso

Phase 1

1 6

Moderna

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Active, not recruiting

MRNA Vaccine

NCT06891417

Clinical

Trials by Indication[1]

mRNA Vaccine1 trial

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

Active, not recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT06891417·1,560 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chlamydia mRNA Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chlamydia mRNA Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chlamydia mRNA Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Chlamydia mRNA Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

mRNA Vaccine1 trial

References

Drug Info

Quick Facts

Related News